Right before the holidays, happy to share our new preprint 🌲 The 3rd main part of my PhD, from a simple idea long before the spatial era boom: how do tissues from different regions of the same tumor differ in immune cell states and TCR clonality?
Thanks to all co-authors for their work and support!
Christina Metoikidou
So happy to be back in beautiful Lisbon for #EACR2025!
Looking forward to the fantastic scientific talks ahead, and to discussing our study on the spatial organization of intratumour immune heterogeneity (poster P-755 tomorrow!)🪻
Excited to share my first post & see the second part of my PhD work published! Our study on mTNBC highlights that baseline clonal expansion of dysfunctional CD8 cells is linked to better response to chemoimmunotherapy.
More here: www.sciencedirect.com/science/arti...
#CD8 #TCellExhaustion #TNBC
The T cell subsetting challenge #immunology
Happy to share that I have been awarded the EACR-Mark Foundation Postdoctoral Fellowship! This funding supports my project on identifying TME signals shaping distinct CD8 T cell states at @danielathommen.bsky.social @nkinl.bsky.social.
Grateful for this opportunity!
Congrats to all the recipients!
It was a pleasure to present my research at #EACR2026, supported by @helloeacr.bsky.social @themarkfdn.bsky.social postdoctoral fellowship. Thank you to all organizers & participants!
Christina Metoikidou
Nature Metabolism
📍 8th Course on Computational Systems Biology of Cancer
“Multimodal data analysis and network modelling to master cancer hallmarks” at Institut Curie.
➡️ Registration open until June 15: training.institut-curie.org/courses/csbc...
Christina Metoikidou
Christina Metoikidou
We are thrilled to support these outstanding scholars! Congratulations, @juliemmazet.bsky.social, @christinamt.bsky.social, and @marthamz.bsky.social! 🎉
Christina Metoikidou
Trends in Immunology
Institut Curie
The Mark Foundation for Cancer Research
Nature Metabolism, Published online: 09 December 2025; doi:10.1038/s42255-025-01415-6Dietary restriction promotes the expansion of effector T cells via ketone bodies, which enhances anti-tumour immunity and synergizes with immunotherapy in mice.
Congratulations to our first EACR-@themarkfdn Postdoctoral Fellowship winners! Julie Mazet, Christina Metoikidou and Martha Zarou 👏
This funding is awarded for a period of three years to support excellent postdoctoral researchers in laboratories throughout Europe.
magazine.eacr.org/congratulati...
Christina Metoikidou delivers the EACR - @themarkfdn.bsky.social Postdoctoral Fellowship Award Lecture on dissecting tissue-resident and circulating trajectories to CD8 T cell dysfunction in the tumour microenvironment at #EACR2026
Chemotherapy combined with immune checkpoint blockade has shown clinical activity in breast cancer. Response, however, occurs in only a low proportion…
Congratulations to our first EACR-@themarkfdn Postdoctoral Fellowship winners! Julie Mazet, Christina Metoikidou and Martha Zarou 👏
This funding is awarded for a period of three years to support excellent postdoctoral researchers in laboratories throughout Europe.
magazine.eacr.org/congratulati...
Analysis of intratumoral immune heterogeneity reveals spatial organisation of immunosuppression in breast cancer https://www.biorxiv.org/content/10.64898/2025.12.18.694622v1
EACR - European Association for Cancer Research
Exploiting specific T cell subset properties bears potential for T cell therapies but is complicated by inconsistencies in T cell subset definitions and markers. Here, we discuss causes for the definition and classification complexities to provide a handle for how to navigate the T cell subset jungle.
